Real-life Experience of Bimekizumab in 27 Obese Patients With Plaque-type Psoriasis: a 24-week Multicenter Retrospective Study

Real-life Experience of Bimekizumab in 27 Obese Patients With Plaque-type Psoriasis: a 24-week Multicenter Retrospective Study

Saved in:

Bibliographic Details
Main Authors:	Zeno Fratton, Vincenzo Maione, Stefano Bighetti, Luca Bettolini, Giuseppe Stinco, Enzo Errichetti
Format:	Article
Language:	English
Published:	Mattioli1885 2025-01-01
Series:	Dermatology Practical & Conceptual
Subjects:	obese bimekizumab psoriasis safety biologic
Online Access:	https://dpcj.org/index.php/dpc/article/view/4893
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Real-World Experience of Bimekizumab in a Cohort of 109 Patients Over 48 Weeks and Identification of Predictive Factors for an Early Super Response and Risk of Adverse Events
by: Fratton Z, et al.
Published: (2025-04-01)

Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study – IL PSO (Italian Landscape Psoriasis)
by: D. Orsini, et al.
Published: (2024-12-01)

Bimekizumab as-needed dosing in patients with psoriasis: a case series
by: Carlota Abbad-Jaime De Aragón, et al.
Published: (2025-12-01)

Adverse events associated with bimekizumab for moderate-to-severe plaque psoriasis: A retrospective, multicenter, post-hoc analysis
by: Nikki Zangenah, BA, et al.
Published: (2025-06-01)

Bimekizumab for the treatment of moderate to severe psoriasis: a real-world experience over 52 weeks from two Italian dermatology clinics
by: E. Mortato, et al.
Published: (2025-12-01)

Gender Influence on Bimekizumab Response in Patients with Psoriasis: Results of a Real-World Multicenter Retrospective Study—IL PSO (Italian Landscape PSOriasis)
by: Helena Gioacchini, et al.
Published: (2025-05-01)

Effective treatment of recalcitrant palmoplantar psoriasis in a patient with skin of color using bimekizumab
by: Emily G. Tocco, BS, et al.
Published: (2025-09-01)

Indirect Comparison Between Bimekizumab and Brodalumab for the Management of Moderate to Severe Psoriasis: A 36-Week Real-Life Study
by: Luca Potestio, et al.
Published: (2025-02-01)

Evaluating the Efficacy of Bimekizumab Across Different Sensitive Areas in Moderate-to-Severe Psoriasis: 52-week Multicentric Real-Life Experience in Lazio, Italy
by: Annunziata Dattola, et al.
Published: (2025-04-01)

Challenging case of tinea corporis and faciei in psoriatic patient treated with bimekizumab: The usefulness of mycological screening before biological therapies
by: Terenzio Cosio, et al.
Published: (2024-12-01)

Severe Paradoxical Scalp Psoriasis Induced by Bimekizumab in a Young Multifailure Hidradenitis Suppurativa Patient
by: Fabrizio Martora, et al.
Published: (2025-02-01)

Efficacy of Bimekizumab in the Management of Refractory Erythrodermic Pityriasis Rubra Pilaris: Clinical Insights
by: Sofia Theotokoglou, et al.
Published: (2025-07-01)

New Therapies in the Biological Treatment of Psoriasis: A Review
by: Mateusz Kamil Ożóg, et al.
Published: (2025-06-01)

Bimekizumab Impact on Patient-Reported Outcomes in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II
by: Vivian Y. Shi, et al.
Published: (2025-07-01)

Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies
by: Philip J. Mease, et al.
Published: (2024-08-01)

Serious generalized pustular psoriasis with evolution to plaque psoriasis: approach with spesolimab
by: Liz S. Gea, et al.
Published: (2024-10-01)

Chronic Plaque Psoriasis
by: K.M. Luba, et al.
Published: (2006-10-01)

Bimekizumab: The First FDA-Approved Dual IL-17A/IL-17F Inhibitor for Plaque Psoriasis &ndash; A Comprehensive Literature Review
by: Al Alshaikh SA, et al.
Published: (2025-08-01)

Serum Levels of 25-Hydroxyvitamin D in Chronic Plaque Psoriasis
by: Ayush Jha, et al.
Published: (2023-03-01)

Serum Levels of 25-Hydroxyvitamin D in Chronic Plaque Psoriasis
by: Ayush Jha, et al.
Published: (2023-03-01)

Oral roflumilast for psoriasis: a real-world 24-week prospective cohort study
by: Ana Maria Lé, et al.
Published: (2025-12-01)

Ustekinumab Efficacy and Safety in Children with Plaque, Erythrodermic and Palmoplanar Forms of Psoriasis: Retrospective Cohort Study
by: Nikolay N. Murashkin, et al.
Published: (2020-12-01)

Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore
by: Wai Sze Agnes Chan, et al.
Published: (2023-07-01)

Tobacco Smoking Was Positively Associated with Disease Relapse at week 24 and 48 Among Patients with Psoriasis Vulgaris in Shanghai: A Prospective Study
by: Shen F, et al.
Published: (2025-07-01)

Efficacy and Safety of Apremilast Over 52 Weeks in Patients with Plaque Psoriasis in High-Impact Areas and Impaired Quality of Life
by: Matthias Augustin, et al.
Published: (2025-05-01)

Efficacy and safety of mirikizumab (LY3074828) in chronic plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials
by: Taimoor Ashraf, et al.
Published: (2025-07-01)

Personalized Secukinumab Treatment in Patients with Plaque Psoriasis Using Model-Informed Precision Dosing
by: Karine Rodriguez-Fernandez, et al.
Published: (2024-12-01)

Lentigines confined to the upper body plaques of a paraplegic psoriasis vulgaris patient
by: Gaye Güldiken Doğruel
Published: (2025-07-01)

Evaluation of the efficacy and safety of cold laser (Diode 808 nm) therapy in the treatment of localized plaque psoriasis: clinical, dermoscopic and ultrastructural study
by: Reham L. Gohar, et al.
Published: (2024-05-01)

Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52
by: Steven R. Feldman, et al.
Published: (2024-12-01)

Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg—IL PSO (Italian Landscape Psoriasis)
by: Mario Valenti, et al.
Published: (2025-04-01)

Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study – IL PSO (Italian landscape psoriasis)
by: Luigi Gargiulo, et al.
Published: (2024-12-01)

Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy
by: Marco May Lee, et al.
Published: (2025-07-01)

A large-scale retrospective study in China explores risk factors for disease severity in plaque psoriasis
by: Huiwei Wang, et al.
Published: (2024-10-01)

Novel Approach for Evaluating the Effectiveness of Biological Drugs in Patients with Plaque Psoriasis: Real-World Experience of a Single-Centre Study in Poland
by: Kimak-Pielas A, et al.
Published: (2025-06-01)

Efficacy of indigo naturalis nanofibrous patches in the treatment of chronic plaque psoriasis: a 4-week prospective, randomized, semi-compartmental paired, positive drug-controlled trial
by: Yuechun Zhao, et al.
Published: (2025-06-01)

Observational study on the therapeutic management and economic burden of adult patients with moderate to severe plaque psoriasis in France – the POP study
by: A. P. Villani, et al.
Published: (2023-12-01)

Efficacy and Safety of Apremilast in Oncological Patients with Moderate-to-Severe Plaque Psoriasis: A 5 years Retrospective Observational Study
by: Lanna C, et al.
Published: (2025-05-01)

Efficacy of Intermittent Fasting in the Management of Chronic Plaque Psoriasis: A Phase IIb Clinical Trial
by: Shekhar Neema, et al.
Published: (2025-05-01)

Effects of Rusanda Spa balneotherapy combined with calcipotriol on plaque psoriasis
by: Golušin Zoran, et al.
Published: (2015-01-01)